AI image · google/nano-banana-2-lite
News
One dated story per official action — scheduling moves and policy changes, tied to their documents.
Screens from this site
- official pinned What goes in News
- official Suvorexant, lemborexant and daridorexant proposed for looser control
- official MGM-15, MGM-16 and mitragynine pseudoindoxyl: a notice of intent, not yet an order
- official Cipepofol, a new propofol-like anaesthetic, is Schedule IV — while propofol itself still is not
- official Cychlorphine, spirochlorphine and two dichloro analogues are Schedule I, 57 days after the notice
- official MGM-15, MGM-16 and mitragynine pseudoindoxyl are Schedule I, 51 days after the notice of intent
- official 7-OH threshold: HHS reopens the comment window until September 10
- official Clobromazolam, medetomidine and six more go before WHO's drug committee in October; FDA takes comments until September 3
- official O-desmethyltramadol is Schedule I, 49 days after the notice of intent
- official List I precursor actions of 2026: two designations final, two still proposed
- official Tianeptine proposed for Schedule I
- official DEA gives notice it intends to schedule dichloro-brorphine analogues
- official Bromazolam temporarily placed in Schedule I, and the June correction to the order
- official Diphenidine proposed for Schedule I — proposed, not scheduled
- official Six synthetic cannabinoids into Schedule I across three weeks
- official 7-hydroxymitragynine: DEA proposes temporary Schedule I above a concentration threshold
- official HHC gets its own Schedule I listing and drug code
- official Clonazolam, etizolam and three more benzodiazepines placed in Schedule I
- official The "cannabimimetic agents" definition now names 18 more substances
- official Two more nitazenes permanently placed in Schedule I, effective February 11
- official 2-FDCK is Schedule I: from January's notice to May's order
- official Schedule III for FDA-approved products and state-licensed medical marijuana — not marijuana itself
- official EMS agencies get their own controlled-substances registration
- official 4-FA placed in Schedule I
- official SUPPORT Act rules for medication-assisted treatment take final form
- official Seizure watch 2025: xylazine at #6, medetomidine and BTMPS in the top 25 for the first time, and fentanyl's share down from its 2022 peak
- official 3-MeO-PCP placed in Schedule I